What is the impact factor of Lancet Neurology?

Lancet Neurology has an impact factor of 22.8 (2024). This places it among the top-tier journals in its field with Lancet Neurology publishes clinical research that directly impacts how neurologists diagnose, treat, and manage patients.

How long does Lancet Neurology take to review?

Lancet Neurology typically takes 2-4 weeks initial decision. The full review process involves 6 main stages: pre-submission inquiry (strongly recommended), full manuscript submission via editorial manager, and peer review.

All Journal Guides

Journal Guide

Lancet Neurology Impact Factor 22.8: Publishing Guide

Q: What is the acceptance rate of Lancet Neurology?

Lancet Neurology has an acceptance rate of ~10%. A common reason for rejection is submitting basic science or preclinical work. Researchers often assume that important mechanistic discoveries will interest Lancet Neurology because of the journal's prestige. They won't. Even beautiful work in animal models or in vitro systems gets desk-rejected immediately. The editors aren't evaluating whether your science is good; they're evaluating whether it fits a journal explicitly focused on clinical medicine. Mouse models of Alzheimer's disease, no matter how new, belong in Nature Neuroscience or Cell, not here.

Q: Is Lancet Neurology peer reviewed?

Yes, Lancet Neurology is fully peer reviewed. All submissions undergo rigorous peer review by Expect 3-4 reviewers including at least one statistical expert for trials. Reviews are single-blind, and Lancet Neurology reviewers tend to be senior clinician-scientists who've run major trials themselves. They'll evaluate not just your methodology but whether your conclusions are justified by your data and whether you've addressed limitations honestly..

Q: What does Lancet Neurology look for in submissions?

Definitive Clinical Trials with Clear Practice Implications: Lancet Neurology wants trials that settle debates, not trials that suggest possibilities. Your sample size needs to be adequately powered for clinically meaningful endpoints, not just statistically significant surrogate markers. The editors don't care if your drug reduces a biomarker by 30% if that doesn't translate to fewer strokes or slower disability progression. They've seen too many papers where the primary endpoint was chosen because it was achievable, not because it mattered to patients.

Q: What should I know before submitting to Lancet Neurology?

Time submissions around major conference presentations. The editors pay attention to the American Academy of Neurology and European Academy of Neurology meeting schedules. Late-breaking abstracts selected for these meetings signal that the research community considers your work important. Submitting your full manuscript shortly after a major presentation keeps momentum and demonstrates external validation of significance.

Lancet Neurology doesn't want basic science findings, no matter how elegant. They want studies that'll change how neurologists treat patients on Monday morning.

22.8

Impact Factor (2024)

~10%

Acceptance Rate

2-4 weeks initial decision

Time to First Decision

What Lancet Neurology Publishes

Lancet Neurology publishes clinical research that directly impacts how neurologists diagnose, treat, and manage patients. This isn't a basic science journal, and it's not interested in mechanistic work unless that work has immediate clinical applications. The editors want phase 3 trials, large observational studies, and definitive diagnostic investigations. They're looking for papers that practicing neurologists will read and implement. If your work won't change clinical practice within the next few years, you're submitting to the wrong journal.

Phase 3 randomized controlled trials in stroke, epilepsy, multiple sclerosis, Parkinson's disease, dementia, and neuromuscular disorders that demonstrate clear efficacy or important negative results.
Large-scale epidemiological studies with over 10,000 participants that reveal new risk factors or challenge existing treatment approaches in neurological conditions.
Diagnostic studies that validate new biomarkers, imaging protocols, or clinical criteria with sufficient sensitivity and specificity for real-world implementation.
Health services research examining treatment disparities, resource allocation, or care delivery models that affect neurological patient outcomes across healthcare systems.
Practice-changing guidelines and consensus statements developed by international expert panels with systematic methodology and clear clinical recommendations.

Editor Insight

“I see too many submissions from excellent researchers who don't understand what we publish. We're not interested in your mouse model, your case series of five patients, or your underpowered phase 2 trial - no matter how interesting the biology. What I want is data that changes practice. When I evaluate a submission, I ask myself: will neurologists worldwide read this paper and treat their next patient differently? If the answer isn't clearly yes, the paper doesn't belong here. The mistakes I see most often come from researchers who've done good clinical research but haven't designed their study with sufficient power or the right endpoints to be definitive. I'd rather see you submit to a specialty journal and build the evidence base than waste everyone's time with a premature submission. Pre-submission inquiries help both of us - they let you know early whether your work fits, and they let me spot promising research I should track.”

What Lancet Neurology Editors Look For

Definitive Clinical Trials with Clear Practice Implications

Lancet Neurology wants trials that settle debates, not trials that suggest possibilities. Your sample size needs to be adequately powered for clinically meaningful endpoints, not just statistically significant surrogate markers. The editors don't care if your drug reduces a biomarker by 30% if that doesn't translate to fewer strokes or slower disability progression. They've seen too many papers where the primary endpoint was chosen because it was achievable, not because it mattered to patients.

Rigorous Methodology That Can Withstand Scrutiny

Trial design must be pre-registered with a detailed statistical analysis plan. The editors will check ClinicalTrials.gov, and they'll notice if your endpoints shifted between registration and publication. Blinding, randomization, and allocation concealment aren't just boxes to check; they're elements the editors evaluate carefully because their readers need to trust the findings. Any deviation from protocol needs explanation, and post-hoc analyses should be clearly labeled as exploratory.

International Relevance and Generalizability

A study from a single academic center, no matter how prestigious, raises questions about generalizability. The editors strongly prefer multi-center, multinational research that demonstrates findings hold across healthcare systems and populations. If you ran your trial only in Northern European centers, you'll need to address how results apply to patients in Asia, Africa, and the Americas. This isn't about political correctness; it's about whether your findings will actually work for the journal's global readership.

Patient-Centered Outcomes That Matter

The journal has moved firmly toward outcomes that patients and families care about. Disability scales, quality of life measures, and functional independence matter more than MRI lesion counts or laboratory values. Your paper needs to include these patient-relevant endpoints, ideally as primary or key secondary outcomes. If you're reporting biomarker changes, you better have long-term clinical follow-up or a very compelling biological rationale for why those changes will eventually matter.

Transparent Reporting of Limitations and Funding

Industry-funded trials aren't automatically rejected, but the editors expect complete transparency about sponsor involvement in design, analysis, and writing. They want to see independent statistical analysis or at least investigator access to raw data. Limitations need honest discussion, not the perfunctory paragraph that gets buried before the conclusion. If your trial had high dropout rates, protocol amendments, or unexpected safety signals, address them directly rather than hoping reviewers won't notice.

Why Papers Get Rejected

These patterns appear repeatedly in manuscripts that don't make it past Lancet Neurology's editorial review:

Submitting basic science or preclinical work

Researchers often assume that important mechanistic discoveries will interest Lancet Neurology because of the journal's prestige. They won't. Even beautiful work in animal models or in vitro systems gets desk-rejected immediately. The editors aren't evaluating whether your science is good; they're evaluating whether it fits a journal explicitly focused on clinical medicine. Mouse models of Alzheimer's disease, no matter how new, belong in Nature Neuroscience or Cell, not here.

Underpowered studies with surrogate endpoints

This is the most common reason for rejection at peer review. Researchers design trials around endpoints they can achieve with available funding rather than endpoints that would actually change practice. A phase 2 trial with 80 patients showing a 25% reduction in MRI lesions doesn't meet the bar. The journal has published hundreds of similar studies, and most of those biomarker improvements never translated to clinical benefit. You need the definitive trial, not the promising pilot.

Poor CONSORT or STROBE adherence

Lancet Neurology editors check reporting guideline compliance rigorously, and many submissions fail this check before reaching reviewers. Your flow diagram must account for every randomized patient. Your table 1 must include all pre-specified baseline characteristics. If you're reporting an observational study, STROBE adherence isn't optional. Sloppy reporting signals sloppy methodology, and the editors have enough high-quality submissions that they don't need to give benefit of the doubt.

Cover letters that summarize the abstract

Editors read hundreds of submissions monthly, and they can read your abstract themselves. What they need from your cover letter is context they can't get elsewhere: why this study matters now, what practice change it enables, and why it fits Lancet Neurology specifically rather than JAMA Neurology or Annals of Neurology. A cover letter that just restates your findings suggests you don't understand what makes a paper right for this particular journal.

Ignoring the global burden of neurological disease

Studies focused narrowly on conditions affecting wealthy countries face an uphill battle. The journal serves neurologists worldwide, and the editors actively seek research relevant to low and middle-income settings. If you're studying rare genetic conditions affecting a few thousand patients globally, you're competing against stroke prevention trials that could help millions. Frame your work's relevance to global neurology, or expect reviewers to question prioritization.

Does your manuscript avoid these patterns?

The quick diagnostic reads your full manuscript against Lancet Neurology's criteria and flags the specific issues most likely to cause rejection.

Run Free Readiness Scan →

Insider Tips from Lancet Neurology Authors

Time submissions around major conference presentations

The editors pay attention to the American Academy of Neurology and European Academy of Neurology meeting schedules. Late-breaking abstracts selected for these meetings signal that the research community considers your work important. Submitting your full manuscript shortly after a major presentation keeps momentum and demonstrates external validation of significance.

Include patient advocacy group perspectives when relevant

The journal increasingly values patient engagement in research design and interpretation. If patient groups helped shape your endpoints, recruited participants, or contributed to dissemination plans, mention this explicitly. It's not required, but it signals alignment with where the journal is heading and demonstrates your work matters to people living with these conditions.

Your competing trial results shouldn't be a surprise

If another major trial in your therapeutic area published while your paper was under review, you need to address it in revision even if reviewers don't ask. The editors will notice the omission, and it looks like you're avoiding inconvenient comparisons. Proactively contextualizing your results against new data demonstrates academic integrity and saves a revision cycle.

Statistical reviewer expertise varies, so be thorough

Lancet Neurology uses specialist statistical reviewers for complex trials, and these reviewers catch things clinical reviewers miss. If you've used propensity score matching, mixed-effects models, or competing risk analysis, your methods section needs enough detail that a statistician can evaluate your choices. Hand-waving about analytical approaches invites requests for raw data sharing or re-analysis.

Negative trials can get accepted if they're definitive

The journal has published important negative trials that stopped ineffective treatments from spreading. If your well-powered, well-designed trial shows a promising intervention doesn't work, that's still practice-changing information. Frame negative results as resolving clinical equipoise rather than failing, and emphasize how your findings prevent patients from receiving futile treatments.

The Lancet Neurology Submission Process

Pre-submission inquiry (strongly recommended)

Response within 5-7 business days

Send a structured inquiry to the editors summarizing your study design, sample size, primary findings, and why results merit publication in Lancet Neurology specifically. Include your abstract and a brief explanation of practice implications. This saves weeks compared to a full submission that gets desk-rejected, and positive responses indicate genuine editorial interest.

Full manuscript submission via Editorial Manager

1-3 days for administrative processing

Prepare your manuscript following Lancet family formatting requirements precisely. This means structured abstract with specific headings, research in context panel summarizing evidence before and after your study, and author contributions using CRediT taxonomy. Missing elements cause administrative delays before your paper even reaches an editor.

Editorial assessment and triage

1-2 weeks for initial decision

The handling editor evaluates fit, novelty, and methodological rigor. About 60-70% of submissions are rejected at this stage without peer review. If your paper passes triage, it goes to external reviewers with clinical and methodological expertise relevant to your topic. Editor selection of reviewers significantly influences the review's focus.

Peer review by clinical and statistical experts

3-5 weeks for review completion

Expect 3-4 reviewers including at least one statistical expert for trials. Reviews are single-blind, and Lancet Neurology reviewers tend to be senior clinician-scientists who've run major trials themselves. They'll evaluate not just your methodology but whether your conclusions are justified by your data and whether you've addressed limitations honestly.

Revision and resubmission

Usually 4-8 weeks allowed for revision

If you receive a revision request, you've cleared the highest hurdle. Respond point-by-point to every comment, tracking changes clearly in your manuscript. Don't argue with reviewers unless you have compelling justification; instead, show how you've addressed concerns. Major revisions that require new analyses or additional data collection may need re-review.

Final acceptance and production

4-6 weeks from acceptance to publication

Accepted papers go through professional copyediting, and you'll review proofs for accuracy. The production team handles figure formatting and online publication. High-impact papers may be selected for press release coordination, and the communications team will contact you about media timing and embargo requirements.

Lancet Neurology by the Numbers

Impact Factor (2024)(Consistently ranks among top 3 clinical neurology journals globally)	22.8
Acceptance Rate(Includes papers surviving initial triage, which filters out most submissions)	~10%
Time to First Decision(Rapid triage means you won't wait months for a desk rejection)	14-21 days
Submissions Per Year(High volume means editors are highly selective about what gets reviewed)	~2,500
Median Days to Publication(From acceptance to online publication with DOI assignment)	~90 days
Altmetric Performance(Papers here get substantial media and social media attention)	Top 5%

Before you submit

Lancet Neurology accepts a small fraction of submissions. Make your attempt count.

The pre-submission diagnostic runs a live literature search, scores your manuscript section by section, and gives you a prioritized fix list calibrated to Lancet Neurology. ~30 minutes.

Run Free Readiness Scan See a sample report

Article Types

Original Research (Articles)

4,500 words excluding abstract, references, tables, figures

Full-length reports of clinical trials, observational studies, and diagnostic investigations. Must include structured abstract, research in context panel, and clear implications for clinical practice.

Review

5,000 words with up to 100 references

Commissioned or pre-approved systematic reviews and narrative reviews on topics of major clinical importance. Must use systematic search methodology and PRISMA guidelines where applicable.

Personal View

2,000 words

Opinion pieces on controversial topics in clinical neurology. Authors must have established expertise in the area and present balanced consideration of opposing perspectives before arguing their position.

Comment

1,000-1,500 words

Short invited commentaries on published articles or on issues in neurological practice. Usually solicited by editors to accompany specific papers or address timely topics.

Series

Varies by topic, typically 3,500-4,500 words per article

Multi-part commissioned reviews covering major neurological conditions or therapeutic areas. Coordinated with editors to ensure consistent quality and avoid overlap between installments.

Landmark Lancet Neurology Papers

Papers that defined fields and changed science:

Höglinger et al., 2024 - Proposed a biological classification of Parkinson's disease based on synuclein, neuronal, and genetic markers
Siderowf et al., 2023 - Assessed heterogeneity in Parkinson's progression using biomarkers from the Parkinson's Progression Markers Initiative
Thompson et al., 2018 - Revised McDonald diagnostic criteria for multiple sclerosis incorporating MRI evidence
Shulman et al., 2010 - Revised UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria for Lewy body disorders
Polman et al., 2011 - Revisions to McDonald criteria for diagnosing multiple sclerosis using MRI and CSF findings
Campbell et al., 2019 - Extended thrombolysis benefit guided by perfusion imaging beyond standard time windows in late-window stroke

Preparing a Lancet Neurology Submission?

Get pre-submission feedback from reviewers who've published in Lancet Neurology and know exactly what editors look for.

Run Free Readiness Scan

Need expert depth? Human review from $1,000

NDA-protected

Confidential

Primary Fields

Stroke and cerebrovascular diseaseMultiple sclerosis and neuroinflammatory disordersParkinson's disease and movement disordersEpilepsy and seizure disordersAlzheimer's disease and dementiasNeuromuscular diseasesHeadache and pain syndromesNeuro-oncologyNeuroinfectious diseasesGlobal neurology and health disparities

Related Journal Guides

All journal guides

All articles

Ready to submit to Lancet Neurology?

A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what Lancet Neurology editors look for.

Need field-expert depth? Human review from $1,000